(19)
(11) EP 4 739 333 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24740409.8

(22) Date of filing: 05.07.2024
(51) International Patent Classification (IPC): 
A61K 38/18(2006.01)
A61K 35/17(2025.01)
A61P 31/12(2006.01)
A61K 39/00(2006.01)
 A61K 31/00(2006.01)
A61P 29/00(2006.01)
C07K 16/22(2006.01)
C12N 5/0783(2010.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/1841; C12N 5/0636; A61P 29/00; A61P 31/12; A61K 35/17; C12N 2501/15; A61K 40/11
(86) International application number:
PCT/EP2024/069010
(87) International publication number:
WO 2025/012121 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 EP 23184044
04.08.2023 EP 23189816

(71) Applicant: Deutsches Rheuma-Forschungszentrum Berlin
10117 Berlin (DE)

(72) Inventors:
  • MASHREGHI, Mir-Farzin
    13089 Berlin (DE)
  • KALLINICH, Tilmann
    10435 Berlin (DE)
  • DUREK, Pawel
    10557 Berlin (DE)
  • GOETZKE, Carl-Christoph
    10115 Berlin (DE)

(74) Representative: Hertin und Partner Rechts- und Patentanwälte PartG mbB 
Kurfürstendamm 63
10707 Berlin
10707 Berlin (DE)

   


(54) TGF-SS INHIBITION AND ENGINEERED T-CELLS FOR THE TREATMENT OF COVID-19 SEQUELAE AND VIRUS-INDUCED HYPERINFLAMMATION